Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...

Donald Trump nominated Robert F. Kennedy Jr., a vaccine skeptic and harsh critic of federal health agencies, to be his ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

BofA Securities cuts Moderna's price target from $110 to $90 due to vaccine sales concerns. Moderna faces tough competition ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Most patients with rheumatoid arthritis or spondyloarthritis had significant antibody responses to COVID vaccine boosters, whether or not their immunomodulatory medications were held.

Moderna posted a profit of $13 million, or 3 cents per share. Sales of its Spikevax COVID vaccine reached $1.8 billion, up ...

Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 $10 ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

RFK Jr. has developed a reputation as a vaccine skeptic and pushed conspiracy theories including one linking vaccines to ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...